Elevation Oncology scores $65m Series B

Elevation Oncology, a developer of precision medicines for patients with genomically defined cancers, has raised $65 million in Series B financing.

Elevation Oncology, a developer of precision medicines for patients with genomically defined cancers, has raised $65 million in Series B financing. The lead backers were venBio Partners and Cormorant Asset Management.

Source: Press Release